Drug delivery device

一种递送装置、药物的技术，应用在药物输送、药物组合、药物的器械等方向，能够解决无法调节给药量、低血糖、症状恶化等问题

Active Publication Date: 2018-08-03
NAT UNIV CORP TOKYO MEDICAL & DENTAL UNIV
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, wearable insulin pumps controlled by microcomputers are gaining popularity mainly in Europe and the United States. However, this device administers insulin according to a preset algorithm and cannot adjust the dosage according to actual changes in blood sugar levels.
Therefore, when an inappropriate amount of insulin is administered, a hypoglycemic state may be induced and sometimes worsened

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug delivery device
  • Drug delivery device
  • Drug delivery device

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0106]The gelling agent (that is, the skeleton structure) uses N-isopropylmethacrylamide (NIPMAAm) and phenylboronic acid monomer (AmECFPBA), and the crosslinking agent uses N,N'-methylenebisacrylamide (MBAAm) , the polymerization initiator uses 2,2'-azobisisobutyronitrile, the above four are mixed at a feed molar ratio of 91.5 / 7.5 / 1 / 0.1, and radical polymerization is carried out in a capillary with a diameter of 1 mm to prepare a gel.

[0107] [chemical 4]

[0108]

[0109] The obtained gel was swelled in a human insulin preparation (Humulin R injection, manufactured by Eli Lilly) solution or PBS at room temperature, and then soaked in 0.1M hydrochloric acid aqueous solution at 37° C. for 1 hour to encapsulate insulin.

[0110] Under physiological conditions (pH 7.4, 37°C), the gel can undergo a phase transition with the normoglycemic level (1g / L) as the threshold, and it was confirmed that the release of insulin is controlled using the cortex formed on the gel surface as ...

Embodiment 2

[0112] One hollow fiber used in a polysulfone membrane dialyzer (APS-15SA4537693003682) manufactured by Asahi Kasei Medical Co., Ltd. was used as the device (inner diameter: 185 μm, membrane thickness: 45 μm). In this example, the device was connected to a commercially available human silicone catheter (4Fr: about 600 μm inner diameter, Primetech Co., Ltd.), which served as a reservoir for supplying insulin.

[0113] Insulin release experiments were performed using a high performance liquid chromatography (HPLC) system (JASCO, Japan) with 2 pumps and internal detectors for detection of refractive index (RI), UV, fluorescence intensity.

[0114] The gel prepared in the same manner as in Example 1 was soaked in PBS containing 130 mg / L FITC-labeled bovine insulin (WAKO, Japan) at 4° C. for 24 hours to encapsulate FITC-labeled insulin in the gel. Next, the gel was filled into the device of the present invention, and the device was quickly placed in a 0.01M hydrochloric acid soluti...

Embodiment 3

[0119] Using the same system as in Example 2, the device used is made by sealing the two ends of 10 hollow fibers. Used. In this example, no reservoir is used.

[0120] The result is as Figure 5 As shown, it was confirmed that as the concentration of glucose in the outer fluid of the hollow fiber increased, the fluorescence intensity increased, and insulin was released from the device. When the glucose concentration decreases, the release of insulin is inhibited.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The purpose of the present invention is to provide an improved device capable of releasing a drug dependent on stimulation by glucose concentration and the like. Provided is a drug delivery device characterized in comprising: a porous body such as hollow yarn that is biocompatible and drug-permeable; a stimulation-responsive gel composition filled into the inner surface side of the porous body; and a drug that is surrounded by the gel composition, on the inner surface side of the porous body.

Description

technical field [0001] The present invention relates to a drug delivery device, and more specifically, to an improved device capable of rapidly adjusting a drug delivery amount in response to stimulation such as glucose concentration in blood. Background technique [0002] Diabetes is characterized by a pathological increase in blood glucose concentration (blood sugar level), and its symptoms range from no symptoms to disturbance of consciousness. Diabetes is known to cause various complications in addition to the symptoms caused by hyperglycemia itself. [0003] The regulation of the blood sugar level in the living body is carried out by various hormones represented by insulin, but the imbalance of this regulation mechanism will lead to the onset of diabetes. Diabetes is basically divided into type 1 and type 2. Type 1 diabetes is characterized by low insulin secretion, while type 2 diabetes has a lot of insulin secretion, but it cannot keep up with the increase in blood s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K9/70A61K38/28A61K47/16A61K47/32A61M5/24A61P3/10
CPCA61K38/28A61K47/16A61K9/0004A61M2025/0057A61M25/0043A61M37/0015A61M5/14248A61M5/329A61M2205/0238A61P3/10C08F220/54C08F230/06C08F222/385A61K47/32A61K9/70A61M5/3291C08F220/56C08F2800/10
Inventor 松元亮松本裕子菅波孝祥田中都宫原裕二
Owner NAT UNIV CORP TOKYO MEDICAL & DENTAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap